Aneuploidy, NIPT Clinical Trial
— IONAOfficial title:
A Safer Pre-Natal Diagnosis Using Free DNA in Maternal Blood
NCT number | NCT01472523 |
Other study ID # | 07H0607101 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | April 2007 |
Est. completion date | December 2019 |
Verified date | June 2020 |
Source | Premaitha Health |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
A diagnostic peripheral maternal blood test taken and the free foetal DNA is analysed and the presence of trisomies using a novel method.
Status | Completed |
Enrollment | 1632 |
Est. completion date | December 2019 |
Est. primary completion date | February 2018 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 16 Years and older |
Eligibility |
Inclusion Criteria: - Patient/subject is willing and able to give informed consent for participation in the study. - Female, aged 16 years or above. - Currently pregnant at time of entry to the study. - Pregnancy having been identified as 'high-risk' by screening test. Exclusion Criteria: - The patient/subject may not enter the study if ANY of the following apply: - The participant herself has Down's Syndrome or other chromosomal abnormality. - Children under 16 - Adults with learning disabilities - Adults who are unconscious or very severely ill - Adults who have a terminal illness - Adults in emergency situations - Adults suffering from a mental illness - Adults with dementia - Prisoners - Young offenders - Adults who are unable to consent for themselves - Any person considered to have a particularly dependent relationship with investigators |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Premaitha Health | Manchester |
Lead Sponsor | Collaborator |
---|---|
Premaitha Health |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Validation of method of novel analysis for Aneuploidy | Analysis of maternal blood by a selective amplification of fetal DNA over maternal DNA within that sample. Patients to be followed up for 1 year. | 2013 Approx | |
Secondary | Optimization of existing methods for maximising ffDNA | Use of novel methods either in conjugation with existing methods or as a substitute for steps in existing methodologies- currently undergoing laboratory development that could increase the titre of fetal DNA within a given sample. Patients will be followed up for 1 year. | up to July 2019 |